Galecto was advised to stop enrolling and treating patients at high dose and certain ones at low dose in its…
Articles by Forest Ray PhD
Tiny particles, or nanoparticles, coated with a peptide called GSE4 prevented some features of idiopathic pulmonary fibrosis (IPF) and eased…
Cynata Therapeutics will begin a preclinical study to investigate the mechanisms underlying the high potency of its…
A new lung-on-a-chip recreates complex lung structures using a patient’s own cells, providing a more precise model for studying disorders…
The two COVID-19 vaccines that recently received emergency approval from the U.S. and other worldwide regulatory agencies are expected…
The first patient has enrolled in a Phase 3 clinical trial testing whether N-acetyl cysteine (NAC), an antioxidant, can…
NeuroScientific Biopharmaceuticals, the Institute for Respiratory Health, and the University of Western Australia (UWA)…
Oral LYT-100 (deupirfenidone) was found to be safe and well-tolerated at all doses in an ongoing Phase 1 trial…
The first patient has enrolled in a clinical trial to understand the effect of Ofev (nindetanib) on adults who…
Bridge Biotherapeutics and Boehringer Ingelheim ended a collaboration and license agreement to develop BBT-877, a potential treatment…